CIITA
CIITA (MHC class II transactivator) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Skin cancer, Colorectal cancer and 4 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. Does not bind DNA. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both PubMed:8402893, PubMed:7749984,. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter. Also mediates enhanced MHC class I transcription; the promoter element requirements for CIITA-mediated transcription are distinct from those of constitutive MHC class I transcription, and CIITA can functionally replace TAF1 at these genes. Activates CD74 transcription. Location: Nucleus; Nucleus, PML body (UniProt). Locus 16p13.13 (HGNC).
- Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
- Lung cancer: Open Targets association 0.51 with lung cancer (MONDO_0008903)
- Non-Hodgkin lymphoma: Open Targets association 0.50 with non-Hodgkin lymphoma (MONDO_0018908)
- Diffuse large B-cell lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (DLBCLNOS)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"CIITA" OR ABSTRACT:"CIITA" OR TITLE:"class II major histocompatibility complex transactivator" OR ABSTRACT:"class II major histocompatibility complex transactivator" OR TITLE:"MHC class II transactivator" OR ABSTRACT:"MHC class II transactivator" OR TITLE:"C2TA" OR ABSTRACT:"C2TA" OR TITLE:"MHC2TA" OR ABSTRACT:"MHC2TA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CIITA, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ciita.json. Licence CC BY-NC 4.0.